LUIZ FELIPE PINHO MOREIRA

(Fonte: Lattes)
Índice h a partir de 2011
16
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

Categoria: review ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • article 0 Citação(ões) na Scopus
    Perspectives of bilateral thoracic sympathectomy for treatment of heart failure
    (2021) SILVA, Raphael dos Santos Coutinho E; ZANONI, Fernando Luiz; SIMAS, Rafael; MOREIRA, Luiz Felipe Pinho
    Surgical neuromodulation therapies are still considered a last resort when standard therapies have failed for patients with progressive heart failure (HF). Although a number of experimental studies have provided robust evidence of its effectiveness, the lack of strong clinical evidence discourages practitioners. Thoracic unilateral sympathectomy has been extensively studied and has failed to show significant clinical improvement in HF patients. Most recently, bilateral sympathectomy effect was associated with a high degree of success in HF models, opening the perspective to be investigated in randomized controlled clinical trials. In addition, a series of clinical trials showed that bilateral sympathectomy was associated with a decreased risk of sudden death, which is an important outcome in patients with HF. These aspects indicates that bilateral sympathectomy could be an important alternative in the treatment of HF wherein pharmacological treatment barely reaches the target dose.
  • article 0 Citação(ões) na Scopus
    Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors. Implications for the Editors' Network
    (2017) ALFONSO, Fernando; ADAMYAN, Karlen; ARTIGOU, Jean-Yves; ASCHERMANN, Michael; BOEHM, Michael; BUENDIA, Alfonso; CHU, Pao-Hsien; COHEN, Ariel; CAS, Livio Dei; DILIC, Mirza; DOUBELL, Anton; ECHEVERRI, Dario; ENC, Nuray; FERREIRA-GONZALEZ, Ignacio; FILIPIAK, Krzysztof J.; FLAMMER, Andreas; FLECK, Eckart; GATZOV, Plamen; GINGHINA, Carmen; GONCALVES, Lino; HAOUALA, Habib; HASSANEIN, Mahmoud; HEUSCH, Gerd; HUBER, Kurt; HULIN, Ivan; IVANUSA, Mario; KRITTAYAPHONG, Rungroj; LAU, Chu-Pak; MARINSKIS, Germanas; MACH, Francois; MOREIRA, Luiz Felipe; NIEMINEN, Tuomo; OUKERRAJ, Latifa; PERINGS, Stefan; PIERARD, Luc; POTPARA, Tatjana; REYES-CAORSI, Walter; RIM, Se-Joong; RODEVAND, Olaf; SAADE, Georges; SANDER, Mikael; SHLYAKHTO, Evgeny; TIMURALP, Bilgin; TOUSOULIS, Dimitris; URAL, Dilek; PIEK, J. J.; VARGA, Albert; LUSCHER, Thomas F.
  • article 21 Citação(ões) na Scopus
    Ethical Issues in the Use of Animal Models for Tissue Engineering: Reflections on Legal Aspects, Moral Theory, Three Rs Strategies, and Harm-Benefit Analysis
    (2017) LIGUORI, Gabriel R.; JERONIMUS, Bertus F.; LIGUORI, Tacia T. de Aquinas; MOREIRA, Luiz Felipe P.; HARMSEN, Martin C.
    Animal experimentation requires a solid and rational moral foundation. Objective and emphatic decision-making and protocol evaluation by researchers and ethics committees remain a difficult and sensitive matter. This article presents three perspectives that facilitate a consideration of the minimally acceptable standard for animal experiments, in particular, in tissue engineering (TE) and regenerative medicine. First, we review the boundaries provided by law and public opinion in America and Europe. Second, we review contemporary moral theory to introduce the Neo-Rawlsian contractarian theory to objectively evaluate the ethics of animal experiments. Third, we introduce the importance of available reduction, replacement, and refinement strategies, which should be accounted for in moral decision-making and protocol evaluation of animal experiments. The three perspectives are integrated into an algorithmic and graphic harm-benefit analysis tool based on the most relevant aspects of animal models in TE. We conclude with a consideration of future avenues to improve animal experiments.
  • article 57 Citação(ões) na Scopus
    17 beta-Estradiol, a potential ally to alleviate SARS-CoV2 infection
    (2020) BREITHAUPT-FALOPPA, Ana Cristina; CORREIA, Cristiano de Jesus; PRADO, Carla Maximo; STILHANO, Roberta Sessa; URESHINO, Rodrigo Portes; MOREIRA, Luiz Felipe Pinho
    Considering that female sexual hormones may modulate the inflammatory response and also exhibit direct effects on the cells of the immune system, herein, we intend to discuss the sex differences and the role of estradiol in modulating the lung and systemic inflammatory response, focusing on its possible application as a treatment modality for SARS-CoV-2 patients. COVID-19 patients develop severe hypoxemia early in the course of the disease, which is silent most of the time. Small fibrinous thrombi in pulmonary arterioles and a tumefaction of endothelial were observed in the autopsies of fatal COVID-19 cases. Studies showed that the viral infection induces a vascular process in the lung, which included vasodilation and endothelial dysfunction. Further, the proportions of CD4+ T and CD8+ T lymphocytes were strongly reduced in patients with severe SARS-CoV-2 infection. Estradiol is connected with CD4+ T cell numbers and increases T-reg cell populations, affecting immune responses to infection. It is known that estradiol exerts a protective effect on endothelial function, activating the generation of nitric oxide (NO) via endothelial nitric oxide synthase. Estrogen attenuates the vasoconstrictor response to various stimuli and induces vasodilation in the pulmonary vasculature during stress situations like hypoxia. It exerts a variety of rapid actions, which are initiated after its coupling with membrane receptors, which in turn, may positively modulate vascular responses in pulmonary disease and help to maintain microvascular flow. Direct and indirect mechanisms underlying the effects of estradiol were investigated, and the results point to a possible protective effect of estradiol against COVID-19, indicating that it may be considered as an adjuvant therapeutic element for the treatment of patients affected by the novel coronavirus.